Venus Remedies

₹1,448As of Sun 8 Nov 2026, 12:00 UTC

NSE:VENUSREMHealthcare

Country India

PE (Fwd) 17.09

TSR 10Y CAGR 28.12%

Div yield 0.69%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.33

PE TTM 18.83

TSR TTM 235.45%

Mkt cap ₹19.36B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹1,593

10.04%

(84.29%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

7.696

Revenue₹B

—

6.002

5.555

6.014

6.529

7.696

8.106

6.41%

17.88

Revenue growth%

—

(7.44)

8.27

8.55

17.88

5.33

8.41

—

49.42

Gross margin%

—

35.52

40.07

40.75

41.79

49.42

49.56

40.75

16.10

Operating margin%

—

4.84

5.08

5.60

8.43

16.10

16.11

5.60

13.36

Net margin%

—

6.79

4.78

4.74

6.94

13.36

13.29

6.79

18.83

P/E ratio (avg)x

—

13.37

10.85

15.30

9.902

7.692

17.96

10.85

15.61

EV/EBITx

—

18.75

10.22

12.95

8.157

6.380

14.82

10.22

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

76.90

EPS₹

—

30.86

19.87

21.31

33.90

76.90

80.62

25.64%

—

126.83

EPS growth%

—

(35.60)

7.25

59.05

126.83

4.84

33.15

—

Bookvalue per sh₹

—

FCF per share₹

—

10.00

Dividend per sh₹

—

10.00

11.60

—

0.69

Div yield (avg)%

—

1.69

0.80

1.69

—

13.00

Payout ratio%

—

13.00

14.39

—

13.37

Shares (diluted)M

—

13.20

13.37

◌13.37

0.32%

—

Buyback yield%

—

(1.30)

—

◌—

—

D/E ratiox

—

19.35

Enterprise value₹B

—

5.444

2.883

4.360

4.487

7.907

19.35

9.78%

—

LT debt₹M

—

Peers (US$206.5M)

Cap (US$)

Hester Biosciences…

213.2M

14.37x

Indoco Remedies Limited

211.4M

62.81x

Syncom Formulations…

203.2M

22.59x

Cresco Labs Inc.

207.4M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

3,377

359.3

Own earn%

—

Sh yield%

0.69

—

Owners

Insiders/Inst%

27.40

1.48

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

5–16

$1 testx

—

Incr. ROIC%

—

Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹7.696B

6.41%

1.00×

Cost of revenue

₹3.893B

0.15%

0.78×

Operating expenses

₹2.564B

8.62%

1.09×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m